Vertex Pharmaceuticals Overview
Vertex Pharmaceuticals Target Price
Analysts' 12-month price predictions for VRTX.
Share Price
$396.12
Average Target Price
$475.88
20.1% upside
20.1% upside8 analysts in the last 4 months
High: $553 | Low: $420
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-08-05 | Truist Financial | $490 | 23.7% upside |  |
| 2025-08-05 | Stifel Nicolaus | $455 | 14.9% upside | |
| 2025-08-05 | UBSEliana Merle | $553 | 39.6% upside | |
| 2025-08-05 | BMO Capital | $530 | 33.8% upside | |
| 2025-08-05 | H.C. Wainwright | $478 | 20.7% upside | |
| 2025-08-05 | Morgan Stanley | $439 | 10.8% upside | |
| 2025-06-17 | RBC CapitalBrian Abrahams | $420 | 6% upside | |
| 2025-05-06 | ScotiabankGreg Harrison | $442 | 11.6% upside | |
| 2025-04-22 | Cantor Fitzgerald | $535 | 35.1% upside | |
| 2025-01-31 | BMO CapitalEvan Seigerman | $545 | 37.6% upside | |
| 2025-01-30 | Wells FargoMohit Bansal | $460 | 16.1% upside | |
| 2025-01-10 | Morgan StanleyTerence Flynn | $456 | 15.1% upside | |
| 2024-12-19 | RBC CapitalBrian Abrahams | $400 | 1% upside | |
| 2024-12-09 | JefferiesMichael Yee | $550 | 38.8% upside | |
| 2024-11-05 | OppenheimerHartaj Singh | $540 | 36.3% upside | |
| 2024-11-05 | RBC CapitalBrian Abrahams | $451 | 13.9% upside | |
| 2024-10-22 | Canaccord GenuityWhitney Ijem | $361 |  8.9% downside | |
| 2024-10-21 | BMO CapitalEvan David Seigerman | $566 | 42.9% upside | |
| 2024-10-21 | Goldman SachsSalveen Richter | $598 | 51% upside | |
| 2024-10-14 | Bank of America SecuritiesGeoff Meacham | $541 | 36.6% upside | |
| 2024-10-09 | RBC CapitalBrian Abrahams | $437 | 10.3% upside | |
| 2024-08-05 | Truist FinancialJoon Lee | $550 | 38.8% upside | |
| 2024-08-05 | OppenheimerHartaj Singh | $550 | 38.8% upside | |
| 2024-08-05 | Wolfe ResearchAndy Chen | $576 | 45.4% upside | |
| 2024-08-02 | H.C. WainwrightAndrew Fein | $600 | 51.5% upside | |
| 2024-06-17 | Argus ResearchJasper Hellweg | $550 | 38.8% upside | |
| 2024-06-11 | RBC CapitalBrian Abrahams | $421 | 6.3% upside | |
| 2024-05-31 | BMO CapitalEvan David Seigerman | $500 | 26.2% upside | |
| 2024-05-07 | Raymond JamesChristopher Raymond | $456 | 15.1% upside | |
| 2024-05-07 | RBC CapitalBrian Abrahams | $424 | 7% upside | |
| 2024-04-11 | H.C. WainwrightAndrew Fein | $462 | 16.6% upside | |
| 2024-04-11 | Evercore ISILiisa Bayko | $438 | 10.6% upside | |
| 2023-02-08 | Morgan Stanley | $285 | 28.1% downside | |
| 2023-02-08 | H.C. Wainwright | $326 | 17.7% downside | |
| 2023-02-08 | Leerink Partners | $365 | 7.9% downside | |
| 2022-11-17 | Argus Research | $340 | 14.2% downside | |
| 2022-08-08 | Morgan Stanley | $253 | 36.1% downside | |
| 2022-08-05 | H.C. Wainwright | $300 | 24.3% downside | |
| 2022-07-12 | Cantor FitzgeraldOlivia Brayer | $365 | 7.9% downside | |
| 2022-07-11 | Stifel NicolausPaul Matteis | $240 | 39.4% downside | |
| 2022-07-02 | Argus ResearchJasper Hellweg | $280 | 29.3% downside | |
| 2022-06-13 | Cowen & Co. | $310 | 21.7% downside | |
| 2022-05-03 | Morgan StanleyMatthew Harrison | $250 | 36.9% downside | |
| 2022-04-22 | Piper Sandler | $249 | 37.1% downside | |
| 2022-04-06 | OppenheimerHartaj Singh | $350 | 11.6% downside | |
| 2022-03-22 | Robert W. BairdBrian Skorney | $240 | 39.4% downside | |
| 2022-03-22 | BMO CapitalEvan Seigerman | $274 | 30.8% downside | |
| 2022-01-27 | J.P. MorganCory Kasimov | $288 | 27.3% downside | |
| 2022-01-27 | Wolfe ResearchAndrew Galler | $282 | 28.8% downside | |
| 2022-01-27 | Morgan StanleyMatthew Harrison | $208 | 47.5% downside | |